Ligand-targeted therapeutics in anticancer therapy

@article{Allen2002LigandtargetedTI,
  title={Ligand-targeted therapeutics in anticancer therapy},
  author={T. Allen},
  journal={Nature Reviews Cancer},
  year={2002},
  volume={2},
  pages={750-763}
}
  • T. Allen
  • Published 2002
  • Medicine
  • Nature Reviews Cancer
  • Cytotoxic chemotherapy or radiotherapy of cancer is limited by serious, sometimes life-threatening, side effects that arise from toxicities to sensitive normal cells because the therapies are not selective for malignant cells. So how can selectivity be improved? One strategy is to couple the therapeutics to antibodies or other ligands that recognize tumour-associated antigens. This increases the exposure of the malignant cells, and reduces the exposure of normal cells, to the ligand-targeted… CONTINUE READING

    Figures, Tables, and Topics from this paper.

    References

    Publications referenced by this paper.
    SHOWING 1-10 OF 145 REFERENCES
    Continuous cultures of fused cells secreting antibody of predefined specificity
    • 15,300
    • PDF
    An Update.
    • 6,197
    • PDF
    Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size.
    • 1,567
    • PDF
    Hepatic drug targeting: phase I evaluation of polymer-bound doxorubicin.
    • 364